Abbott study links CGM use in Type 2 diabetes patients on basal insulin to 45% lower 12-month mortality risk
Bitget2026/09/27 22:05- Abbott flagged new real-world data linking continuous glucose monitoring use to fewer deaths in Type 2 diabetes patients on basal insulin.
- Results will be presented at EASD starting Sept. 28, 2026, supporting broader adoption of Libre in a large insulin-treated population.
- A separate observational analysis tied Libre use to fewer hospitalizations for acute diabetes events in Type 2 diabetes patients.
- Abbott also plans to present additional FreeDM2 trial analyses showing faster, sustained improvements in glucose control following Libre 3 initiation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Welltower Down Over 5%, On Pace for Largest Percent Decrease Since April 2025 -- Data Talk
Goldman Sachs Adjusts Price Target on Roper Technologies to $468 From $410
BUZZ-Centene shares rise after raising 2026 earnings forecast
Coca-Cola raises full-year guidance against trend, zero-sugar cola sales surge by 16%, North America sales unexpectedly remain flat | Earnings Highlights
Coca-Cola's third-quarter results exceeded expectations, and the full-year organic revenue growth guidance has been raised again to at least 5%. Coke Zero Sugar sales surged 16%, driven by strong international market demand, but North American sales were unexpectedly flat, while categories like water and sports drinks faced pressure. The share price has increased by about 33% this year, significantly outperforming PepsiCo.
Crypto prices
More
